LBA93Registrational results of LOXO-292 in patients with RET-altered thyroid cancers

ConclusionsLOXO-292 had marked antitumor activity in RET-altered thyroid cancer and was well tolerated. These data will form the basis of an FDA new drug application in late 2019.Clinical trial identificationNCT03157128.Legal entity responsible for the studyLoxo Oncology.FundingLoxo Oncology.DisclosureL.J. Wirth: Advisory / Consultancy: Eisai; Speaker Bureau / Expert testimony: Bayer; Advisory / Consultancy: Genentech; Advisory / Consultancy: Loxo; Advisory / Consultancy: Merck. E. Sherman: Advisory / Consultancy: Loxo Oncology; Advisory / Consultancy: COTA consulting; Advisory / Consultancy: Novartis; Advisory / Consultancy: Goldilocks; Advisory / Consultancy: Eisai; Advisory / Consultancy: Bristol-Myers Squibb. A. Drilon: Advisory / Consultancy: Ignyta; Advisory / Consultancy: Loxo Oncology; Advisory / Consultancy: TP therapeutics; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: Takeda/Ariad/Millenium; Advisory / Consultancy: Helsinn; Advisory / Consultancy: Beigene; Advisory / Consultancy: BergenBio; Advisory / Consultancy: Hengrui Therapeutics; Advisory / Consultancy, Research grant / Funding (institution): Exelixis; Advisory / Consultancy: Bayer; Advisory / Consultancy: Tyra Biosciences; Advisory / Consultancy: Verastem; Advisory / Consultancy: MORE Health; Advisory / Consultancy: Lilly; Research grant ...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research